Company intelligence / Profile preview

Imvaq Therapeutics

New York, New York, United States

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Imvaq’s lead candidate MQ710, an armed Modified Vaccinia Ankara (MVA)-based viral immunotherapy expressing membrane-bound Flt3L and OX40L, is in a Phase 1 clinical trial in advanced solid tumors, including various skin cancers and sarcoma, in combination and monotherapy settings; no detailed clinical outcome data have yet been publicly reported, but robust preclinical data and an active Phase 1 trial are noted.[3][6][8]

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyGene therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

MQ710

Partnerships

ProBioGen (service and commercial product license to use AGE1.CR.pIX cell line and platform for MVA-based cancer immunotherapy manufacturing)[1]

Beyond the preview

Go deeper on Imvaq Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imvaq Therapeutics.

Explore the full profile